ADVANCED SOLID TUMORS

This early-phase study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, measure drug levels in the body, a…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including a type of lung cancer. The drug works by activating the body's immune T-cells to fight cancer. The main goals were to check safety, find the best dose, and see how the d…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if…

This early-phase study tested a new drug, BAT8006, in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the highest safe dose, and determine the best dose for future studies. This is a first step in…

This early-phase study tested an experimental drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had stopped responding to treatment. The main goals were to find a safe dose and see if the drug …

This early-phase study tested a new oral drug called ASC61 in 18 adults with advanced solid tumors that had stopped responding to standard treatments or had no standard options. The drug works by blocking PD-L1, a protein that helps tumors hide from the immune system. The main go…

This early-phase study tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and to see how the drug moves through the body and affects tumors. Researchers also lo…

This early-phase study tested a new drug called KL340399, which is injected directly into tumors. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors.

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This early-stage study tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors. The study is …

This early-phase trial tested a new drug called ZGGS15 in 22 adults with advanced solid tumors that no longer responded to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might shrink tumors.

This study tested a new treatment called Anti-ALPP CAR-T cells in 5 people with advanced solid tumors that had not responded to standard therapies. The treatment uses a patient's own immune cells, modified to find and attack cancer cells that have a specific marker (ALPP). The ma…

This study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check safety and side effects, and to see if the drug helps control the cancer. Participants received IBI334 alone, and re…

This early-phase study tested a new drug called SHR-A1811 in 396 adults with advanced solid tumors that have a specific marker (HER2) and have stopped responding to standard treatments. The main goals were to check the drug's safety and how the body processes it, while also looki…

This early-phase study tested a new drug, AMG 305, in 37 adults with advanced solid tumors who had no other treatment options. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the drug moved throu…

This study allowed people with certain cancers who had already benefited from the drug tazemetostat in earlier studies to keep receiving it. The main goal was to track long-term safety and side effects. Participants had already shown clinical benefit and continued treatment under…

This study tested a new drug called MK-1200 in 13 people with advanced stomach, esophageal, bile duct, or pancreatic cancer that had stopped responding to other treatments. The goal was to find the safest dose and see if the drug could shrink tumors. The study was completed and f…

This early-stage study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. The study is now complete, …

This early-stage study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The study is now complete, but it does not offer …

This study tested a new drug called BMS-986408, given alone or with other cancer drugs (nivolumab and ipilimumab), in 68 people with advanced solid tumors that had not responded to other treatments. The main goal was to check safety and find the best dose. This is an early-stage …

This early-phase study tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. Researchers also looked for signs that the …

This study looked at how itraconazole, a strong CYP3A4 inhibitor, changes the way the body processes lurbinectedin in people with advanced solid tumors. It involved 14 participants and used a two-way crossover design to measure drug levels in the blood. The goal was to understand…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…